Want to see IN:LYKALABS full AI Analyst Report?

Lyka Labs Limited (LYKALABS) Price & Analysis

1 Followers

LYKALABS Stock Chart & Stats

₹94.40

-₹1.55(-0.97%)

At close: Jan 08 4:00 PM EST

₹94.40

-₹1.55(-0.97%)

Day’s Range― - ―

52-Week Range₹44.49 - ₹104.80

Previous CloseN/A

Volume78.41K

Average Volume (3M)5.76K

Market Cap

₹2.71B

Enterprise Value₹2.06B

Total Cash (Recent Filing)₹18.93M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Nov 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.50

Shares Outstanding36,152,710

10 Day Avg. Volume2,234

30 Day Avg. Volume5,764

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.74

Price to Sales (P/S)1.25

P/FCF Ratio-21.33

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Deleveraging And Positive EquitySubstantial debt reduction and positive equity improve financial resilience compared with earlier periods of high leverage and negative equity. This repair can reduce financing pressure, preserve strategic flexibility, and provide a stronger foundation for navigating pharmaceutical operating volatility over the next several quarters.

Positive Operating Cash FlowPositive operating cash flow indicates that the core business continues to generate some cash from operations even when reported earnings are weak. Although the amount is modest, this supports working-capital needs and offers an internal funding contribution for ongoing pharmaceutical activities.

Established Pharmaceutical PlatformAn operating platform spanning pharmaceutical development, production, and marketing provides an established base for recurring product sales across healthcare channels. This business model can support continuity over the medium term, provided the company improves execution and restores consistent profitability.

Bears Say

Revenue Decline And Renewed LossesThe latest deterioration shows that demand conversion, pricing, or cost absorption has not yet translated into stable financial performance. Falling revenue combined with a return to substantial net losses weakens earnings visibility and can constrain investment in products, marketing, and operations.

Persistently Negative Free Cash FlowRepeated negative free cash flow indicates that operating cash generation is insufficient to cover ongoing investment and other cash requirements. The sharper deterioration in 2026 reduces self-funding capacity, potentially increasing reliance on financing or limiting the pace of business development.

Volatile Earnings And Leverage HistoryRecent balance-sheet repair does not eliminate the risk signaled by the company’s history of losses, elevated debt-to-equity, and prior negative equity. This record suggests earnings quality and financial control remain inconsistent, making future performance less dependable than the current capital structure alone implies.

Lyka Labs Limited News

Lyka Labs Files SEBI Dematerialisation Compliance Certificate for September Quarter

An announcement from Lyka Labs Limited ( ($IN:LYKALABS) ) is now available. Lyka Labs Limited has submitted to...

2d ago

Lyka Labs Completes Amalgamation With Lyka Exports, Boosts Authorised Capital

An update from Lyka Labs Limited ( ($IN:LYKALABS) ) is now available. Lyka Labs Limited has secured final...

6M ago

NCLT Clears Merger of Lyka Exports With Lyka Labs

Lyka Labs Limited ( ($IN:LYKALABS) ) has shared an update. Lyka Labs Limited has announced that the National...

7M ago

Lyka Labs Says NCLT Reserves Order on Amalgamation Scheme After FEMA Compliance Filing

Lyka Labs Limited ( ($IN:LYKALABS) ) just unveiled an announcement. Lyka Labs Limited has updated exchanges on the...

8M ago

Lyka Labs Confirms SEBI Dematerialisation Compliance for December Quarter

Lyka Labs Limited ( ($IN:LYKALABS) ) has provided an update. Lyka Labs Limited has reported that its registrar...

9M ago

Lyka Labs Updates on Amalgamation Process

Lyka Labs Limited ( ($IN:LYKALABS) ) has issued an announcement. Lyka Labs Limited has provided an update on...

12M ago

LYKALABS FAQ

What was Lyka Labs Limited’s price range in the past 12 months?

Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹104.80 in the past 12 months.

What is Lyka Labs Limited’s market cap?

Lyka Labs Limited’s market cap is ₹2.71B.

When is Lyka Labs Limited’s upcoming earnings report date?

Lyka Labs Limited’s upcoming earnings report date is Nov 14, 2026 which is in 35 days.

How were Lyka Labs Limited’s earnings last quarter?

Lyka Labs Limited released its earnings results on Aug 10, 2026. The company reported ₹0.571 earnings per share for the quarter.

Is Lyka Labs Limited overvalued?

According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyka Labs Limited pay dividends?

Lyka Labs Limited does not currently pay dividends.

What is Lyka Labs Limited’s EPS estimate?

Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lyka Labs Limited have?

Lyka Labs Limited has 36,152,710 shares outstanding.

What happened to Lyka Labs Limited’s price movement after its last earnings report?

Lyka Labs Limited reported an EPS of ₹0.571 in its last earnings report. Following the earnings report the stock price went up 1.996%.

Which hedge fund is a major shareholder of Lyka Labs Limited?

Currently, no hedge funds are holding shares in IN:LYKALABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lyka Labs Limited

Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.